Biotechnology firm Ocugen has successfully completed patient enrollment for its pivotal Phase 3 clinical trial, known as liMeliGhT, marking a significant step forward for its lead gene therapy candidate. The announcement comes just one day before the company is scheduled to release its quarterly financial results. With 140 participants now enrolled, this trial represents the largest clinical study to date for a gene therapy targeting Retinitis pigmentosa. Initial data from the study is anticipated in the first quarter of 2027.
Ambitious Regulatory Timeline Set
Ocugen has outlined an aggressive path toward commercialization. The company intends to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration in the third quarter of 2026. If approved, this would pave the way for a potential market launch in 2027. The European Medicines Agency (EMA) has already indicated that data from the U.S.-based liMeliGhT study will be acceptable for a regulatory submission in Europe, streamlining the path to approval across major markets.
The liMeliGhT trial is evaluating OCU400 for the treatment of Retinitis pigmentosa (RP), an inherited retinal disease that can lead to blindness. A key differentiator for this therapy is its gene-agnostic approach, meaning it is designed to be suitable for a broad patient population. This includes children as young as three years old and adults with late-stage disease. Participants have been randomized in a 2:1 ratio into either the treatment or control group. The primary goal is to measure improvement in visual function after twelve months using a specific test known as the LDNA.
Supportive Long-Term Data and a Diversified Pipeline
The Phase 3 program is bolstered by encouraging long-term data from earlier studies. Results from a Phase 1/2 trial spanning three years showed that 88% of treated patients experienced either improvement or stabilization in their condition compared to untreated eyes. Researchers observed an average visual acuity gain of two lines on an eye chart, a benefit seen across various genetic mutation types. Importantly, no new treatment-related adverse events emerged during this extended follow-up period.
Should investors sell immediately? Or is it worth buying Ocugen?
Ocugen’s development efforts extend beyond OCU400. The company is advancing two additional gene therapy candidates. OCU410, targeting dry age-related macular degeneration, has reported positive initial twelve-month data. Meanwhile, OCU410ST for Stargardt disease is undergoing evaluation in a Phase 2/3 study, with interim results expected by mid-2026 and a potential regulatory filing planned for the first half of 2027. Overall, Ocugen’s strategy aims to submit three separate marketing applications by 2029.
Financial Position and Leadership
To support these ambitious clinical programs, Ocugen strengthened its balance sheet in early 2026 through a capital raise that generated $20.85 million in proceeds. Management believes these funds provide a financial runway extending into the fourth quarter of 2026. The company also recently appointed Rita Johnson-Greene as its new Chief Financial Officer. She brings over two decades of experience in the healthcare sector to the role.
Investors are now looking ahead to the company’s upcoming financial report. Ocugen is set to disclose its results for the fourth quarter and full year 2025 on March 4, 2026. The completion of the liMeliGhT enrollment is a central component of the company’s broader plan, with the planned BLA submission for OCU400 representing the first of several anticipated regulatory milestones.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from March 3 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 3.
Ocugen: Buy or sell? Read more here...
